🏛️ Verified NIH Record • Updated 2026-08-27

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) (NCT06637423)

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Merck Sharp & Dohme LLC

🩺 Plain-English Summary (8th-Grade Level)

The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (10 items) and avoid the listed exclusions (9 items).

Location: Michael G Oefelein Clinical Trials ( Site 0053) — Bakersfield, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria: The key exclusion criteria include but are not limited to the following:
  • Newly diagnosed low-grade non-muscle invasive bladder cancer (Ta NMIBC) in the bladder
  • Past or current history of high-grade (Ta or T1 or CIS) NMIBC, muscle invasive bladder cancer (MIBC) or metastatic urothelial carcinoma (UC)
  • Has a condition that would prohibit normal voiding (or hold bladder voiding for 1 to 2 hours)
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease, and/or blepharitis, or severe corneal disease that prevents and/or delays corneal healing
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Chron's disease, ulcerative colitis, or chronic diarrhea)
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (13 Sites)

  • Michael G Oefelein Clinical Trials ( Site 0053) — Bakersfield, California
  • Moffitt Cancer Center ( Site 0057) — Tampa, Florida
  • Northwestern University ( Site 0051) — Chicago, Illinois
  • Johns Hopkins University ( Site 0055) — Baltimore, Maryland
  • Princess Margaret Cancer Centre ( Site 0003) — Toronto, Ontario
  • CIUSSS de l'Estrie-CHUS ( Site 0002) — Sherbrooke, Quebec
  • Hôpital Claude Huriez ( Site 0012) — Lille, Nord
  • HENRI MONDOR HOSPITAL ( Site 0011) — Créteil, Val-de-Marne
  • Gustave Roussy ( Site 0013) — Villejuif, Val-de-Marne
  • Erasmus Medisch Centrum ( Site 0032) — Rotterdam, South Holland
  • Hospital Universitario Virgen de la Victoria ( Site 0043) — Málaga, Andalusia
  • Hospital Universitario 12 de Octubre ( Site 0042) — Madrid,
  • St Bartholomew s Hospital ( Site 0061) — London, London, City of

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗